Company intelligence / Profile preview

Shenzhen Fangku Pharmaceutical

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Shenzhen Fangku Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the research and development of innovative small molecule drugs for metabolic diseases. The company's primary focus is on developing next-generation treatments for Type 2 diabetes, including GPR119 agonists and fixed-dose combination therapies. Fangku Pharmaceutical aims to address unmet medical needs in the metabolic space through efficient drug design and clinical validation. Their lead programs are currently undergoing clinical evaluation in China to establish safety and efficacy profiles.

Therapeutic areas: EndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shenzhen Fangku Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Fangku Pharmaceutical.

Explore the full profile